Fda grants accelerated approval for padcev® (enfortumab vedotin-ejfv) with keytruda® (pembrolizumab) for first-line treatment of locally advanced or metastatic urothelial cancer

– first treatment option combining an antibody-drug conjugate plus a pd-1 inhibitor in this patient population – tokyo and bothell, wash. , april 3, 2023 /prnewswire/ -- astellas pharma inc. (tse: 4503, president and ceo: naoki okamura, "astellas") and seagen inc. (nasdaq: sgen) today announced the u.s. food and drug administration (fda) has granted padcev® (enfortumab vedotin-ejfv) with keytruda® (pembrolizumab) accelerated approval in the u.s. as a combination therapy for the treatment of adult patients with locally advanced or metastatic urothelial cancer (la/muc) who are not eligible to receive cisplatin-containing chemotherapy.
SGEN Ratings Summary
SGEN Quant Ranking